Roche to launch global study of Elevidys following EU rejection
Roche will launch a global Phase III trial of its Duchenne muscular dystrophy (DMD) gene therapy Elevidys (delandistrogene moxeparvovec), after…
All articles by Abigail Beaney
Abigail Beaney
Abigail Beaney is the editor of Clinical Trials Arena. Abigail has expertise in clinical trial regulation, trial design, outsourcing, and cell and gene therapies. Abigail also has covered news and has a wealth of knowledge across several therapy areas including neurodegenerative, infectious and metabolic diseases. Abigail holds a first-class BA (Hons) degree in Journalism from the University of Central Lancashire in the United Kingdom. She has also obtained the National Qualification in Journalism through the UK's media industry body, the National Council for the Training of Journalists. Contact Abigail
-
-
Developers back Alzheimer’s drugs despite report suggesting lack of efficacy
Eli Lilly and Eisai have backed their Alzheimer’s disease drugs despite research finding the mechanism of action may be less…
-
PDS Biotech’s stock up on colorectal cancer trial success
PDS Biotech’s stock has jumped nearly 25% after its tumour-targeting fused antibody drug conjugate (ADC) elicited a 78% response in patients…
-
OCT East Coast 2026: overcoming FDA volatility and global uncertainty
Since the Trump Administration reclaimed the White House a little over a year ago, several changes with global consequences have…
-
Lilly’s Jaypirca racks up fourth Phase III CLL win
Eli Lilly’s Jaypirca (pirtobrutinib) has succeeded in its fourth Phase III trial in chronic lymphocytic leukaemia (CLL). The Phase III…
-
FDA cracks down on sponsor and researchers’ failure to publish trial data
The US Food and Drug Administration (FDA) has reminded more than 2,200 sponsors and researchers to publicly publish their clinical…
-
AbbVie’s Elahere succeeds in Phase II platinum-sensitive ovarian cancer trial
AbbVie’s Elahere has shown a 62.7% objective response rate (ORR) in patients with platinum-sensitive ovarian cancer (PSOC) in a Phase…
-
Preparation is key to understanding global trade compliance for trials
For global studies, investigational material and active pharmaceutical ingredients (API) are often shipped to sites in different countries from a…
-
Verastem Oncology’s combo shows two-year durability in ovarian cancer
Verastem Oncology’s combination therapy has shown durability in patients with recurrent low-grade serous ovarian cancer (LGSOC). The data, presented during…
-
Spinogenix’s Fragile X Syndrome drug shows normalisation of brain function
Spinogenix’s Fragile X Syndrome (FXS) drug is the first to show rescued well-established resting EEG abnormalities, suggesting a normalisation of…